The rs8176740 and rs512770 Genetic Variants of the Gene Increased the Risk of COVID-19, as well as the Plasma Concentration Platelets.

We conducted a case-control study in order to evaluate whether gene polymorphisms were associated with a high risk of developing COVID-19 in a cohort of patients. Six gene polymorphisms (rs651007 /, rs579459 /, rs495828 , rs8176746 , rs8176740 , and rs512770 /) were determined using TaqMan genotyping assays in a group of 415 COVID-19 patients and 288 healthy controls. The distribution of rs651007 /, rs579459 /, rs495828 /, and rs8176746 / polymorphisms was similar in patients and healthy controls. Nonetheless, under co-dominant (OR = 1.89, pC = 6 × 10), recessive (OR = 1.98, pC = 1 × 10), and additive (OR = 1.36, pC = 3 × 10) models, the genotype of the rs8176740 polymorphism increased the risk of developing COVID-19. In the same way, under co-dominant, recessive, and additive models, the genotype of the rs512770 / polymorphism was associated with a high risk of developing COVID-19 (OR = 1.87, pC = 2 × 10; OR = 1.87, pC = 5 × 10; and OR = 1.35, pC = 4 × 10, respectively). On the other hand, the and haplotypes were associated with a high risk of COVID-19 (OR = 5.45, pC = 1 × 10 and OR = 6.33, pC = 1 × 10, respectively). In addition, the rs8176740 genotype was associated with high-platelet plasma concentrations in patients with COVID-19. Our data suggested that the rs512770 and rs8176740 polymorphisms increased the risk of developing COVID-19 and the plasma concentration of platelets.